You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 4, 2024

Claims for Patent: 7,423,135

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,423,135

Title:	.beta.-actin and rpS21 promoters and uses thereof
Abstract:	The invention relates to isolation of novel .beta.-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent .beta.-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
Inventor(s):	Estes; Scott D. (Framingham, MA), Zhang; Weiqun (Southborough, MA)
Assignee:	Genzyme Corporation (Cambridge, MA)
Application Number:	10/874,242
Patent Claims:	1. An isolated nucleic acid sequence comprising a nucleotide sequence that has promoter activity and is at least 95% identical to the nucleotide sequence set forth in SEQ ID NO:1 over the entire length of SEQ ID NO:1. 2. A vector comprising the promoter of claim 1. 3. The vector of claim 2, wherein the promoter is operably linked to a heterologous nucleic acid encoding a protein. 4. The vector of claim 3, wherein the heterologous nucleic acid encodes a therapeutic protein. 5. The vector of claim 4, wherein the therapeutic protein is selected from the group consisting of acid sphingomyelinase (ASM), .alpha.-glucosidase (GAA), and tissue plasminogen activator (tPA). 6. An isolated host cell transfected with the vector of claim 2. 7. The host cell of claim 6, wherein the host cell is a Chinese hamster ovary (CHO) cell. 8. A method of producing a protein comprising: (a) culturing a host eukaryotic cell transfected with the vector of claim 3; and (b) recovering the protein. 9. The method of claim 8, wherein the protein is an antibody. 10. The method of claim 9, wherein the antibody binds to a TGF-.beta. family member. 11. The method of claim 10, wherein the protein is a therapeutic protein. 12. The method of claim 11, wherein the therapeutic protein is selected from the group consisting of acid sphingomyelinase (ASM), .alpha.-glucosidase (GAA), and tissue plasminogen activator (tPA). 13. The method of claim 11, wherein the therapeutic protein is selected from the group consisting of insulin, thyrogen stimulating hormone, erythropoietin, glucocerebrosidase, and .alpha.-galactosidase. 14. The method of claim 8, wherein the host eukaryotic cell is a mammalian cell. 15. The isolated nucleic acid sequence of claim 1, comprising the nucleotide sequence of ATCC Deposit No. PTA-5309. 16. The isolated nucleic acid sequence of claim 1, wherein the nucleotide sequence that has promoter activity is at least 97% identical to the nucleotide sequence set forth in SEQ ID NO:1 over the entire length of SEQ ID NO:1. 17. The isolated nucleic acid sequence of claim 16, wherein the nucleotide sequence that has promoter activity is at least 99% identical to the nucleotide sequence set forth in SEQ ID NO:1 over the entire length of SEQ ID NO:1.

Details for Patent 7,423,135

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	THYROGEN	thyrotropin alfa	For Injection	020898	11/30/1998	⤷ Try a Trial	2023-06-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.